HomeSmall Caps
Share

CG Oncology's stock rose 346% following its IPO. Wall Street sees even greater potential.

Maria Dranishnikova

Maria Dranishnikova

Oninvest reporter
CG Oncology went public in December 2024, and its stock price has since soared 346% / Photo: Nasdaq

CG Oncology went public in December 2024, and its stock price has since soared 346% / Photo: Nasdaq

Shares of biotech company CG Oncology soared nearly 14% on November 16, reaching an all-time high. Its bladder cancer therapy showed exceptional results in a key clinical trial. The company’s stock has risen 346% from its IPO price, and Wall Street sees further upside potential.

Details

CG Oncology shares surged nearly 14% on the Nasdaq on November 16, reaching $84.78. This marks the highest closing price ever for the company's stock.

The rally began after the company released preliminary data from the third and final phase of clinical trials for its bladder cancer therapy, called creostimogen.

The company tested it on patients with non-muscle-invasive bladder cancer, which means the tumor had not yet penetrated the muscle layer of the bladder. Currently, BCG therapy is used to treat this condition, but in about 40% of cases, it is ineffective, leading to recurrences and bladder removal.

A study by CG Oncology showed that, after 17 months of follow-up, the risk of recurrence among patients taking its drug decreased by 68% compared to the control group. The biotech company reported no serious side effects.

He plans to submit an application to the U.S. Food and Drug Administration (FDA) for the approval of creostimogen in March 2027, and then seek to expand the drug’s indications, according to a press release. For investors, this expansion is just as important as the published data, Barron’s reports. In the second quarter of 2027, the company plans to submit a second application with additional indications.

A Freedom Finance Global analyst has picked three promising companies from different sectors amid the tech rout / Photo: Stockinasia / Shutterstock.com

Where to invest $1,000 amid the AI selloff: Snacks, med tech, and real estate

What Analysts Are Saying

Wall Street reacted enthusiastically to the data.

The reduction in the risk of recurrence reported by the company is “exceptional” and exceeds the 30–40% range which management and investors had hoped for, wrote TD Cowen analyst Tyler Van Buren, whose opinion is cited by BioPharma Dive. “The data exceeded even the most optimistic expectations,” the publication quotes RBC Capital Markets analyst Leonid Timashev as saying.

“This is a compelling result that exceeds even the highest standards we have set. The data represent the most compelling result from a randomized trial ever observed in this segment,” said Morgan Stanley analyst Sean Laaman, as quoted by Barron’s.

Timashev believes that, if approved, peak sales of creostimogen in the U.S. could reach $3.2 billion by 2035.

CG Oncology held its IPO in January 2024, selling 23 million shares at $19 each. The stock price soared 346% from the offering price (compared to the closing price on November 16).

In total, the company's stock has 14 "buy" recommendations from Wall Street analysts, with one more advising investors to hold the biotech stock. The average price target is $101, which is 19% higher than the stock's closing price on November 16.

Share

Trending

Stock Screener
Buy
Sell
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
Small Caps
Investment and Finance News